Welcome to our dedicated page for Odyssey Therapeutics news (Ticker: ODTX), a resource for investors and traders seeking the latest updates and insights on Odyssey Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Odyssey Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Odyssey Therapeutics's position in the market.
Odyssey Therapeutics (NASDAQ: ODTX) priced an upsized IPO of 15,500,000 shares at $18.00 per share, with a 30-day underwriter option for up to 2,325,000 additional shares. A concurrent private placement of 1,388,889 shares to a TPG affiliate was also announced. Gross proceeds are expected to be approximately $304 million before fees. Common stock is expected to begin trading on May 8, 2026, with the offering expected to close on or about May 11, 2026, subject to customary closing conditions.